Cross Country Healthcare, Inc. (CCRN)
NASDAQ: CCRN · Real-Time Price · USD
10.20
-0.10 (-0.97%)
At close: Apr 28, 2026, 4:00 PM EDT
10.20
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Cross Country Healthcare Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cross Country Healthcare stock have an average target of 14.15, with a low estimate of 9.00 and a high estimate of 18.61. The average target predicts an increase of 38.73% from the current stock price of 10.20.
Analyst Consensus: Buy
* Price targets were last updated on Mar 19, 2026.
Analyst Ratings
The average analyst rating for Cross Country Healthcare stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 4 | 3 | 3 | 4 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Hold → Buy Upgrades $11 → $15 | Hold → Buy | Upgrades | $11 → $15 | +47.06% | Mar 19, 2026 |
| Benchmark | Benchmark | Hold → Strong Buy Upgrades $14 | Hold → Strong Buy | Upgrades | $14 | +37.25% | Mar 5, 2026 |
| Wedbush | Wedbush | Hold Initiates $11 | Hold | Initiates | $11 | +7.84% | Feb 3, 2026 |
| UBS | UBS | Hold Maintains $17 → $9 | Hold | Maintains | $17 → $9 | -11.76% | Dec 9, 2025 |
| Barrington Research | Barrington Research | Hold Maintains $19 | Hold | Maintains | $19 | +82.45% | Jun 17, 2025 |
Financial Forecast
Revenue This Year
996.07M
from 1.05B
Decreased by -5.52%
Revenue Next Year
1.05B
from 996.07M
Increased by 5.01%
EPS This Year
0.11
from -2.93
EPS Next Year
0.28
from 0.11
Increased by 148.98%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.0B | 1.1B | |||
| Avg | 996.1M | 1.0B | |||
| Low | 941.9M | 982.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.5% | 11.1% | |||
| Avg | -5.5% | 5.0% | |||
| Low | -10.7% | -1.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.18 | 0.42 | |||
| Avg | 0.11 | 0.28 | |||
| Low | 0.03 | 0.20 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 278.1% | |||
| Avg | - | 149.0% | |||
| Low | - | 76.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.